Vericel sees Q4 revenue $65M, consensus $62.6M

MACI net revenue expected to be approximately $56.7 million, representing 22% growth, marking the sixth straight quarter of 20%+ MACI growth; Burn Care net revenue expected to be approximately $8.3 million, representing 31% growth, consisting of approximately $7.8 million of Epicel revenue and $0.5 million of NexoBrid revenue; Positive adjusted EBITDA and Operating Cash Flow expected for the 14th straight quarter; Gross margin expected to be greater than 70%; Adjusted EBITDA margin expected to be approximately 30%; Highest number of MACI implants, implanting surgeons, surgeons taking biopsies and MACI biopsies in a quarter since launch; Highest number of Epicel biopsies in a quarter since 2021; NexoBrid commercial launch in the U.S., with over 50 burn centers submitting packages to Pharmacy and Therapeutics (P&T) committees and over 25 burn centers with P&T committee approvals.